Plain-English translation of NCT06267183 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage safety study of a medication called designed to treat idiopathic pulmonary fibrosis, a serious lung disease. Researchers are testing the medication in healthy volunteers to understand how it moves through the body and whether it causes any side effects. This is one of the first steps in development before the medication could be tested in patients with lung disease.
Before any new medication can be given to people with a disease, researchers must first confirm it is safe in healthy people and understand how the body processes it. This trial is designed to gather that essential safety information.
You likely qualify if…
You likely don't qualify if…
You would visit the study center for screening to confirm you are healthy and eligible. If accepted, you would receive a single dose of either the new medication or a placebo (inactive treatment) and stay under medical observation. The researchers would monitor your blood pressure, breathing, heart rate, and take blood samples at multiple time points to track how your body responds to the treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai Synvida Biotechnology Co.,Ltd.
Enrollment target
~53 participants
Started
January 2024
Primary completion
November 2026
Age range
18 Years – 45 Years
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.